



# Recombinant Human Claudin 18.2 VLP (DAG-WT1229)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Species</b>	Human
<b>Purity</b>	> 95% as determined by HPLC
<b>Conjugate</b>	N/A
<b>Applications</b>	ELISA, SPR
<b>Molecular Weight</b>	29 kDa
<b>Reconstitution</b>	Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.
<b>Format</b>	Lyophilized
<b>Size</b>	100 µg, 500 µg
<b>Buffer</b>	Lyophilized from 0.22um filtered solution in PBS, pH 7.4. Normally 8% trehalose is added as protectant before lyophilization
<b>Preservative</b>	None
<b>Storage</b>	Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week

## BACKGROUND

<b>Introduction</b>	Claudin-18.2 (CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues
---------------------	--

and abnormal overexpression in a range of malignancies. Multiple clinical trials of CLDN18.2-targeted therapies, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADCs), and chimeric antigen receptor (CAR) T-cell therapies, are ongoing, with some showing promising early results.

---

<b>Keywords</b>	Claudin-18.2; CLDN18.2
-----------------	------------------------

---

## GENE INFORMATION

<b>UniProt ID</b>	P56856-2
-------------------	----------

---